Zura Bio to Present Phase 2 Trial Design for Systemic Sclerosis Treatment at World Congress
Event summary
- Zura Bio's Phase 2 TibuSURE trial design for systemic sclerosis (SSc) accepted for poster presentation at the 9th Systemic Sclerosis World Congress.
- Trial evaluates dual IL-17A and BAFF inhibition with tibulizumab (ZB-106), a novel bispecific antibody.
- Study aims to enroll 80 adults with diffuse cutaneous systemic sclerosis (dcSSc), randomized 1:1 to tibulizumab or placebo.
- Primary endpoint is change from baseline in modified Rodnan Skin Score at Week 24; topline results expected in H1 2027.
The big picture
Zura Bio's presentation at the Systemic Sclerosis World Congress highlights the growing focus on dual-pathway inhibition in autoimmune diseases. The Phase 2 TibuSURE trial represents a strategic shift toward addressing both inflammatory and fibrotic processes in SSc, a rare and debilitating condition with limited treatment options. The success of this approach could set a new benchmark for SSc therapies and potentially expand into other autoimmune indications.
What we're watching
- Clinical Efficacy
- Whether dual IL-17A and BAFF inhibition will demonstrate superior efficacy in SSc compared to existing treatments.
- Regulatory Pathway
- The pace at which Zura Bio can advance tibulizumab through Phase 2 and into potential Phase 3 trials.
- Competitive Landscape
- How Zura Bio positions tibulizumab against other emerging therapies targeting SSc.
Related topics